Fundraising Fox
Axil Capital
Venture capitalTokyo · Seed–Late Stage · 7 people tracked
Find your way into Axil Capital
Sign up to see every warm intro you have to Axil Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Axil Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Axil Capital pursues a strategy of creating value in the life sciences venture ecosystem by identifying and nurturing transformational biotech and healthcare technologies across the full investment spectrum. The firm diversifies its portfolio across biopharmaceuticals, platform technologies, medical devices, digital health, and healthcare services. The investment thesis emphasizes establishing synergies between Japan's biotech ecosystem and global markets to build commercially viable enterprises with sustainable returns while addressing transformational needs in healthcare and medical innovation.
Source: firm website, verified Aug 5, 2026.
Team · 7 people
from the firm's website & public directories
Kimihito Usui is a Senior Principal at Axil Capital Partners (Axil Capital Advisors K.K.), focusing on early-stage biotech investment across the US, Japan, and Taiwan. He holds a Ph.D. in pharmaceutical sciences from the University of Tokyo and worked as a researcher on artificial cell models and later as a lead researcher at a drug discovery venture, where he handled preclinical study design, budget management, fundraising, and business development, publishing 12 peer-reviewed papers. Since 2016 he has worked in life science and healthcare investment, establishing his firm's first direct biotech investment scheme in a securities-based principal investment division and completing direct investments in nine companies across the US and Japan, two of which listed on NASDAQ.
What they invest in
from 5 of 5 portfolio companiesBiotech ×4Deep Tech ×2Healthtech ×2AI & Machine Learning ×1Digital Health ×1Longevity ×1Medical Devices ×1
HQs:Japan×2United States×2
Investments · 5 tracked
founders shown can be your intro pathBy year:2021 · 22020 · 12019 · 14 dated
LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.
BiotechDeep TechHealthtechLongevity
Co-investorsAsahi Kasei Corporate Venture CapitalFast Track InitiativeRemiges Ventures, Inc.4BIO CapitalAstellas Venture Management LLCDCI Partners Co. Ltd.
MabGenesis is a Japanese startup biopharmaceutical company that commercializes decades of academic antibody research to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use.
BiotechDeep TechHealthtech
Co-investorsBeyond Next VenturesLong Black Partners
BiotechMedford, US
Giovanni Traverso(Director)inRobert Langer(Director)Carl Schoellhammer(Executive Officer, Director)inAmy Schulman(Director)
Co-investorsTaiwania Capital
TechsoMed develops BioTrace, an FDA-cleared software platform for image-guided minimally invasive cancer therapy that uses AI to provide real-time 3D visualization, tumor margin control, needle path planning, and post-ablation tissue response prediction.
AI & Machine LearningDigital HealthMedical Devices
Co-investorsNextLeap VenturesHelios Climate Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Frequently asked questions
- How many investments has Axil Capital made?
- Axil Capital has 5 tracked investments.
- What stage does Axil Capital invest at?
- Axil Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Axil Capital focus on?
- Axil Capital focuses on Biotech, Digital Health, Medical Devices.
- Where is Axil Capital located?
- Axil Capital is headquartered in Tokyo, JP.
Images
Co-investors · 2
Astellas Venture Management (AVM) is the wholly-owned corporate venture arm of Astellas, providing equity investments to private, early-stage biotechnology companies developing therapeutic programs and platform technologies for drug discovery.
Remiges Ventures is a venture capital firm focused on life sciences and drug discovery, and runs an incubation fund (RDiscovery Fund) for early-stage drug discovery seeds.
Firms observed investing alongside Axil Capital, from public investor directories. Shared companies are the overlap with Axil Capital's recorded portfolio.
Similar investors
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
The Blue Venture Fund is a partnership among participating Blue Cross Blue Shield companies, the BCBS Association, and Sandbox Industries that invests in healthcare technology, healthcare services, and clinical sciences companies. It aims to reduce costs and improve health outcomes for Blue Plan members.